Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In a new study published in journal Scientific Reports, scientists at NDORMS and Queen Mary University of London have identified reasons underpinning the failure of inflammation to resolve in disorders of musculoskeletal soft tissues such as tendons.

Tendinopathy is a common global disease burden, causing pain and disability. These injuries require prolonged convalescence and there are currently no effective treatments. In the study by Dakin et al. the authors investigated why tendon inflammation fails to resolve in some patients with chronic disease. They studied profiles of pro-inflammatory and inflammation resolving lipids in tendon stromal fibroblasts isolated from patients with tendinopathy and compared them with those derived from healthy donors. Cells from patients with tendinopathy displayed a pro-inflammatory profile and dysregulated resolution responses compared to cells isolated from healthy volunteers. Incubating tendon stromal cells in tissue protective pro-resolving compounds including the aspirin stable isoform 15-epi-LXA4 induced the production of other proresolving lipid mediators and moderated the pro-inflammatory phenotype of diseased tendon stromal cells.

 The investigators noted that the effects of 15-epi-LXA4 treatment were more profound in healthy compared to diseased tendon stromal cells. They identified that cells from tendinopathy patients displayed enhanced ability to convert proresolving mediators to metabolites that carry reduced biological actions. Diseased tendon tissues and cells highly expressed an enzyme (15-PGDH) implicated in the inactivation of tissue protective proresolving mediators. Inhibition of 15-PGDH significantly reduced the further conversion of proresolving mediators and moderated the inflammatory phenotype of diseased tendon cells. These findings suggest that chronic inflammation in musculoskeletal soft tissues may result from dysregulated resolution responses. The authors propose that a dual pronged approach, using pro-resolving mediators together with inhibitors to 15-PGDH represents a novel therapeutic strategy to reduce local tendon inflammation and promote tissue repair. 

Figure 1

Spectra identifying the further metabolites of pro-resolving mediators in tendon stromal cells isolated from healthy volunteers (HV) and patients with tendon disease (TD). Cells from tendinopathy patients displayed enhanced ability to convert tissue protective proresolving mediators to metabolites that carry reduced biological actions. Staining shows cells from patients with tendinopathy highly express 15-PGDH, implicated in the inactivation of proresolving mediators.

Spectra-identifying-the-further-metabolites-of-pro-resolving-mediators.png

read THE FULL STUDY on Scientific Report:

Increased 15-PGDH expression leads to dysregulated resolution responses in stromal cells from patients with chronic tendinopathy. Stephanie G Dakin, Lucy Ly, Romain A. Colas, Udo Oppermann, Kim Wheway, Bridget Watkins, Jesmond Dalli, Andrew J Carr.

 

 

 

Similar stories

Plaster cast or metal pins to treat a broken wrist? The results are in.

An Oxford study published in The BMJ has found the use of metal K-wires (commonly known as ‘pins’) to hold broken wrist bones in place while they heal are no better than a traditional moulded plaster cast.

Professor Chris Buckley has joined the Kennedy Institute as Director of Clinical Research

Moving to the University of Oxford with the Arthritis Therapy Acceleration Programme (A-TAP) will help accelerate the discovery of new treatments for inflammatory diseases.

Behind enemy lines: research finds a new ally in the fight against cardiovascular disease hidden within the vessel wall itself

A new study reveals the existence of a powerful ally in the fight against cardiovascular disease, a protective subset of vascular macrophages expressing the C-type lectin receptor CLEC4A2, a molecule which fosters “good” macrophage behaviour within the vessel wall.

More effective treatment found for patients hospitalised with COVID-19 pneumonia

A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.

NDORMS researchers honoured in the Recognition Of Distinction Scheme 2021

Sally Hopewell and John Christianson have been awarded the title of ‘Full Professor’ in the University of Oxford’s Recognition Of Distinction Scheme 2021.

New Oxford-Zeiss Centre of Excellence opens at the University of Oxford

The Kennedy Institute for Rheumatology and the Institute of Developmental and Regenerative Medicine announce the launch of the Oxford-Zeiss Centre of Excellence, providing state-of-the-art imaging technologies to lead future discoveries in global health and disease.